Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
GLP-1 Receptor Agonist | Weight Loss & Diabetes
Overview
Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated significant efficacy through appetite suppression and glycemic control. The 7-day half-life enables convenient weekly dosing.
Key benefits
- 15-20% average body weight reduction
- Established cardiovascular protection
- Convenient once-weekly dosing options
- Comprehensive safety data from extensive trials
- Flexible injectable and oral formulations
Mechanism of action
Mimics native GLP-1, binding to receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via hypothalamic pathways.
Molecular data
- Type
- GLP-1 receptor agonist
- Half-life
- ~7 days (168 hours)
Sequence
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Indications
What the research community uses this compound for, with self-reported effectiveness.
Weight Loss
Diabetes
Metabolic
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 0.25mg | Weekly x 4 weeks, then increase | — |
| — | 2.4mg | Weekly (after 16-week titration) | — |
| — | 0.5-1mg | Weekly | — |
| — | 0.5-1mg | Weekly | — |
| — | 0.25-2.4mg | Weekly (individualized) | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 3mg | Daily x 30 days | — |
| — | 7mg | Once daily | — |
| — | 14mg | Once daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
Contraindications
- Personal or family history of medullary thyroid cancer
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or breastfeeding
- History of pancreatitis
Monitoring
- Blood glucose levels
- Signs of pancreatitis
- Thyroid nodules
- Kidney function
References
Primary literature and clinical-trial data informing this entry.